Allergan plc Ordinary Shares (AGN) was Reiterated by Mizuho to “Neutral” according to the research note released today. The brokerage firm has raised the Price Target to $ 246 from a previous price target of $232 . Mizuho advised their investors in a research report released on Aug 5, 2016.
Many Wall Street Analysts have commented on Allergan plc Ordinary Shares. Company shares were Reiterated by Leerink Partners on Jul 27, 2016 to “Outperform”, Firm has raised the Price Target to $ 294 from a previous price target of $272 .Credit Suisse Initiated Allergan plc Ordinary Shares on Jul 25, 2016 to “Outperform”, Price Target of the shares are set at $327.Shares were Reiterated by Mizuho on May 13, 2016 to “Neutral” and Lowered the Price Target to $ 232 from a previous price target of $250 .
On the company’s financial health, Allergan plc Ordinary Shares reported $3.04 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on May 10, 2016. Analyst had a consensus of $3.01. The company had revenue of $3796.00 million for the quarter, compared to analysts expectations of $3949.70 million. The company’s revenue was up 48.1% compared to the same quarter last year.
Allergan plc Ordinary Shares opened for trading at $254.26 and hit $255.25 on the upside on Thursday, eventually ending the session at $253.45, with a gain of 0.36% or 0.92 points. The heightened volatility saw the trading volume jump to 21,42,314 shares. Company has a market cap of $100,254 M.
In a different news, on Jun 6, 2016, Maria Teresa Hilado (CFO) purchased 661 shares at $241.57 per share price. According to the SEC, on May 12, 2016, Nesli Basgoz (director) sold 459 shares at $225.10 per share price. On Aug 24, 2015, Brent L Saunders (CEO) purchased 1,000 shares at $301.94 per share price, according to the Form-4 filing with the securities and exchange commission.